SANTA MONICA, Calif. , June 28, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation and Human Capital Committee of the Company’s

Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 SANTA MONICA, Calif. , June 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT) today announced a capacity investment

Company expects to complete submission of the NDA using the 505(b)(2) pathway, as previously agreed upon with the FDA, in the second half of 2022 SANTA MONICA, Calif. , June 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT) today announced the filing of the first

SANTA MONICA, Calif. , May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will

SANTA MONICA, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022 , and provided a

SANTA MONICA, Calif. , May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022 , after the

SANTA MONICA, Calif. , April 29, 2022 /PRNewswire/ --  Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022 , that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC.  Opiant had no knowledge of the press release

Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioid OPNT003 met the primary endpoint of non-inferiority, which was designed to assess whether nasal nalmefene performed as well or better

SANTA MONICA, Calif. , March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021

SANTA MONICA, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr.